25 XP   0   0   10

Laboratorios Farmaceuticos ROVI
Buy, Hold or Sell?

Let's analyse Rovi together

PenkeI guess you are interested in Laboratorios Farmaceuticos ROVI. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Laboratorios Farmaceuticos ROVI. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Laboratorios Farmaceuticos ROVI

I send you an email if I find something interesting about Laboratorios Farmaceuticos ROVI.

Quick analysis of Rovi (30 sec.)










What can you expect buying and holding a share of Rovi? (30 sec.)

How much money do you get?

How much money do you get?
€2.83
When do you have the money?
1 year
How often do you get paid?
80.0%

What is your share worth?

Current worth
€10.48
Expected worth in 1 year
€11.30
How sure are you?
92.5%

+ What do you gain per year?

Total Gains per Share
€3.43
Return On Investment
4.2%

For what price can you sell your share?

Current Price per Share
€80.65
Expected price per share
€61.10 - €
How sure are you?
50%

1. Valuation of Rovi (5 min.)




Live pricePrice per Share (EOD)

€80.65

Intrinsic Value Per Share

€9.77 - €29.04

Total Value Per Share

€20.26 - €39.52

2. Growth of Rovi (5 min.)




Is Rovi growing?

Current yearPrevious yearGrowGrow %
How rich?$587.8m$484.2m$107m18.1%

How much money is Rovi making?

Current yearPrevious yearGrowGrow %
Making money$46m$53.9m-$7.9m-17.2%
Net Profit Margin20.1%23.7%--

How much money comes from the company's main activities?

3. Financial Health of Rovi (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#91 / 1031

Most Revenue
#53 / 1031

Most Profit
#41 / 1031

Most Efficient
#81 / 1031

What can you expect buying and holding a share of Rovi? (5 min.)

Welcome investor! Rovi's management wants to use your money to grow the business. In return you get a share of Rovi.

What can you expect buying and holding a share of Rovi?

First you should know what it really means to hold a share of Rovi. And how you can make/lose money.

Speculation

The Price per Share of Rovi is €80.65. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rovi.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rovi, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €10.48. Based on the TTM, the Book Value Change Per Share is €0.20 per quarter. Based on the YOY, the Book Value Change Per Share is €0.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.65 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rovi.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps1.071.3%1.121.4%1.211.5%0.710.9%0.410.5%
Usd Book Value Change Per Share0.100.1%0.220.3%0.250.3%0.290.4%0.210.3%
Usd Dividend Per Share0.000.0%0.710.9%1.021.3%0.460.6%0.280.4%
Usd Total Gains Per Share0.100.1%0.931.1%1.281.6%0.750.9%0.490.6%
Usd Price Per Share65.12-52.02-55.67-45.18-30.15-
Price to Earnings Ratio15.15-11.84-16.07-21.85-60.45-
Price-to-Total Gains Ratio659.97-165.98-198.84-126.90-107.94-
Price to Book Ratio5.74-4.64-6.37-5.35-4.68-
Price-to-Total Gains Ratio659.97-165.98-198.84-126.90-107.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share87.239105
Number of shares11
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.710.46
Usd Book Value Change Per Share0.220.29
Usd Total Gains Per Share0.930.75
Gains per Quarter (11 shares)10.198.21
Gains per Year (11 shares)40.7732.85
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1311031201323
2621972412556
39329113613889
4124391548150122
51564819510163155
61875823612276188
72186827714288221
824977318162101254
928087359182113287
1031197400203126320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%64.01.01.097.0%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%17.03.00.085.0%35.05.00.087.5%53.06.07.080.3%
Dividend per Share3.00.01.075.0%11.00.01.091.7%18.00.02.090.0%32.00.08.080.0%45.00.021.068.2%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%37.03.00.092.5%58.04.04.087.9%

Fundamentals of Rovi

About Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products. in Spain and internationally. The company's principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; hositak products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. the company provides products for cardiology, osteoarticular/women's health, anaesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Fundamental data was last updated by Penke on 2024-03-12 17:46:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Laboratorios Farmaceuticos ROVI.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Rovi earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Rovi to the Biotechnology industry mean.
  • A Net Profit Margin of 22.0% means that €0.22 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 22.0%. The company is making a huge profit. +2
  • The TTM is 20.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ22.0%TTM20.1%+1.8%
TTM20.1%YOY23.7%-3.6%
TTM20.1%5Y18.4%+1.8%
5Y18.4%10Y13.2%+5.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ22.0%-171.8%+193.8%
TTM20.1%-205.8%+225.9%
YOY23.7%-262.1%+285.8%
5Y18.4%-455.6%+474.0%
10Y13.2%-589.0%+602.2%
1.1.2. Return on Assets

Shows how efficient Rovi is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Rovi to the Biotechnology industry mean.
  • 6.4% Return on Assets means that Rovi generated €0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 6.4%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 5.1%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ6.4%TTM5.1%+1.4%
TTM5.1%YOY6.2%-1.1%
TTM5.1%5Y4.4%+0.7%
5Y4.4%10Y3.1%+1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4%-12.5%+18.9%
TTM5.1%-12.2%+17.3%
YOY6.2%-11.2%+17.4%
5Y4.4%-13.4%+17.8%
10Y3.1%-14.7%+17.8%
1.1.3. Return on Equity

Shows how efficient Rovi is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Rovi to the Biotechnology industry mean.
  • 9.5% Return on Equity means Rovi generated €0.10 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 9.5%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 7.8%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ9.5%TTM7.8%+1.8%
TTM7.8%YOY10.9%-3.1%
TTM7.8%5Y7.0%+0.8%
5Y7.0%10Y5.0%+2.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.5%-15.8%+25.3%
TTM7.8%-15.7%+23.5%
YOY10.9%-13.9%+24.8%
5Y7.0%-18.3%+25.3%
10Y5.0%-19.2%+24.2%

1.2. Operating Efficiency of Laboratorios Farmaceuticos ROVI.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Rovi is operating .

  • Measures how much profit Rovi makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Rovi to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM19.0%-19.0%
TTM19.0%YOY30.4%-11.4%
TTM19.0%5Y21.2%-2.2%
5Y21.2%10Y15.1%+6.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.1%+299.1%
TTM19.0%-210.1%+229.1%
YOY30.4%-279.7%+310.1%
5Y21.2%-459.9%+481.1%
10Y15.1%-596.9%+612.0%
1.2.2. Operating Ratio

Measures how efficient Rovi is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.12 means that the operating costs are €1.12 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 1.125. The company is inefficient in keeping operating costs low. -1
  • The TTM is 0.842. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ1.125TTM0.842+0.283
TTM0.842YOY0.696+0.146
TTM0.8425Y0.793+0.049
5Y0.79310Y0.852-0.059
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1252.861-1.736
TTM0.8423.193-2.351
YOY0.6963.615-2.919
5Y0.7935.560-4.767
10Y0.8527.396-6.544

1.3. Liquidity of Laboratorios Farmaceuticos ROVI.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Rovi is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.55 means the company has €2.55 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 2.549. The company is able to pay all its short-term debts. +1
  • The TTM is 2.393. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.549TTM2.393+0.155
TTM2.393YOY2.023+0.371
TTM2.3935Y2.640-0.246
5Y2.64010Y2.602+0.038
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5493.986-1.437
TTM2.3934.440-2.047
YOY2.0235.552-3.529
5Y2.6406.158-3.518
10Y2.6026.492-3.890
1.3.2. Quick Ratio

Measures if Rovi is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Rovi to the Biotechnology industry mean.
  • A Quick Ratio of 0.84 means the company can pay off €0.84 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.844. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.949. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.844TTM0.949-0.105
TTM0.949YOY0.991-0.042
TTM0.9495Y1.179-0.230
5Y1.17910Y1.317-0.138
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8443.638-2.794
TTM0.9494.168-3.219
YOY0.9915.515-4.524
5Y1.1796.012-4.833
10Y1.3176.209-4.892

1.4. Solvency of Laboratorios Farmaceuticos ROVI.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Rovi assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Rovi to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.32 means that Rovi assets are financed with 32.1% credit (debt) and the remaining percentage (100% - 32.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.321. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.358. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.321TTM0.358-0.038
TTM0.358YOY0.439-0.081
TTM0.3585Y0.366-0.007
5Y0.36610Y0.365+0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3210.335-0.014
TTM0.3580.330+0.028
YOY0.4390.267+0.172
5Y0.3660.367-0.001
10Y0.3650.378-0.013
1.4.2. Debt to Equity Ratio

Measures if Rovi is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Rovi to the Biotechnology industry mean.
  • A Debt to Equity ratio of 47.5% means that company has €0.48 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The MRQ is 0.475. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.567. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.475TTM0.567-0.092
TTM0.567YOY0.791-0.223
TTM0.5675Y0.587-0.019
5Y0.58710Y0.581+0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4750.376+0.099
TTM0.5670.398+0.169
YOY0.7910.334+0.457
5Y0.5870.429+0.158
10Y0.5810.476+0.105

2. Market Valuation of Laboratorios Farmaceuticos ROVI

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Rovi generates.

  • Above 15 is considered overpriced but always compare Rovi to the Biotechnology industry mean.
  • A PE ratio of 15.15 means the investor is paying €15.15 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The EOD is 20.293. Based on the earnings, the company is fair priced.
  • The MRQ is 15.148. Based on the earnings, the company is fair priced.
  • The TTM is 11.842. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD20.293MRQ15.148+5.146
MRQ15.148TTM11.842+3.305
TTM11.842YOY16.068-4.226
TTM11.8425Y21.847-10.005
5Y21.84710Y60.452-38.605
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.293-2.643+22.936
MRQ15.148-2.418+17.566
TTM11.842-2.742+14.584
YOY16.068-4.123+20.191
5Y21.847-6.257+28.104
10Y60.452-6.478+66.930
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The EOD is 32.034. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 23.911. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 2.802. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD32.034MRQ23.911+8.123
MRQ23.911TTM2.802+21.109
TTM2.802YOY-9.553+12.354
TTM2.8025Y-15.171+17.973
5Y-15.17110Y20.043-35.214
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD32.034-3.244+35.278
MRQ23.911-2.939+26.850
TTM2.802-3.478+6.280
YOY-9.553-5.592-3.961
5Y-15.171-8.473-6.698
10Y20.043-8.881+28.924
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Rovi is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.74 means the investor is paying €5.74 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Laboratorios Farmaceuticos ROVI:

  • The EOD is 7.693. Based on the equity, the company is overpriced. -1
  • The MRQ is 5.742. Based on the equity, the company is overpriced. -1
  • The TTM is 4.643. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD7.693MRQ5.742+1.951
MRQ5.742TTM4.643+1.099
TTM4.643YOY6.369-1.726
TTM4.6435Y5.348-0.704
5Y5.34810Y4.682+0.666
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.6932.124+5.569
MRQ5.7422.041+3.701
TTM4.6432.118+2.525
YOY6.3692.915+3.454
5Y5.3483.682+1.666
10Y4.6824.114+0.568
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Laboratorios Farmaceuticos ROVI compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0910.203-55%0.234-61%0.265-66%0.192-52%
Book Value Per Share--10.48410.369+1%8.304+26%7.717+36%5.597+87%
Current Ratio--2.5492.393+6%2.023+26%2.640-3%2.602-2%
Debt To Asset Ratio--0.3210.358-11%0.439-27%0.366-12%0.365-12%
Debt To Equity Ratio--0.4750.567-16%0.791-40%0.587-19%0.581-18%
Dividend Per Share---0.654-100%0.946-100%0.426-100%0.263-100%
Eps--0.9941.032-4%1.116-11%0.660+50%0.381+161%
Free Cash Flow Per Share--0.6290.278+126%0.864-27%0.289+118%0.153+312%
Free Cash Flow To Equity Per Share--0.629-0.167+127%0.147+328%-0.001+100%0.025+2430%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--29.038--------
Intrinsic Value_10Y_min--9.771--------
Intrinsic Value_1Y_max--2.292--------
Intrinsic Value_1Y_min--0.677--------
Intrinsic Value_3Y_max--7.357--------
Intrinsic Value_3Y_min--2.309--------
Intrinsic Value_5Y_max--12.990--------
Intrinsic Value_5Y_min--4.227--------
Market Cap4141651710.000+25%3120909710.8002534046667.473+23%2774435639.910+12%2262519884.324+38%1495048512.653+109%
Net Profit Margin--0.2200.201+9%0.237-7%0.184+19%0.132+66%
Operating Margin---0.190-100%0.304-100%0.212-100%0.151-100%
Operating Ratio--1.1250.842+34%0.696+62%0.793+42%0.852+32%
Pb Ratio7.693+25%5.7424.643+24%6.369-10%5.348+7%4.682+23%
Pe Ratio20.293+25%15.14811.842+28%16.068-6%21.847-31%60.452-75%
Price Per Share80.650+25%60.20048.093+25%51.465+17%41.769+44%27.873+116%
Price To Free Cash Flow Ratio32.034+25%23.9112.802+753%-9.553+140%-15.171+163%20.043+19%
Price To Total Gains Ratio884.166+25%659.973165.984+298%198.839+232%126.897+420%107.940+511%
Quick Ratio--0.8440.949-11%0.991-15%1.179-28%1.317-36%
Return On Assets--0.0640.051+27%0.062+4%0.044+48%0.031+105%
Return On Equity--0.0950.078+23%0.109-13%0.070+37%0.050+91%
Total Gains Per Share--0.0910.857-89%1.180-92%0.690-87%0.455-80%
Usd Book Value--587897459.800591341863.025-1%484253292.600+21%452383381.840+30%324112150.740+81%
Usd Book Value Change Per Share--0.0990.220-55%0.253-61%0.286-66%0.207-52%
Usd Book Value Per Share--11.34011.216+1%8.983+26%8.347+36%6.054+87%
Usd Dividend Per Share---0.707-100%1.023-100%0.460-100%0.285-100%
Usd Eps--1.0751.116-4%1.207-11%0.714+50%0.412+161%
Usd Free Cash Flow--35295871.00015700875.500+125%50356920.950-30%16787443.150+110%8800873.455+301%
Usd Free Cash Flow Per Share--0.6810.301+126%0.934-27%0.313+118%0.165+312%
Usd Free Cash Flow To Equity Per Share--0.681-0.181+127%0.159+328%-0.001+100%0.027+2430%
Usd Market Cap4480024654.707+25%3375888034.1722741078280.205+23%3001107031.691+12%2447367758.873+38%1617193976.137+109%
Usd Price Per Share87.239+25%65.11852.022+25%55.670+17%45.182+44%30.150+116%
Usd Profit--55716203.60046062842.375+21%53995489.325+3%33717183.935+65%19702110.843+183%
Usd Revenue--253805761.200224319971.325+13%221125981.650+15%167509790.430+52%119669336.360+112%
Usd Total Gains Per Share--0.0990.927-89%1.276-92%0.747-87%0.492-80%
 EOD+4 -4MRQTTM+19 -16YOY+17 -185Y+22 -1310Y+22 -13

3.2. Fundamental Score

Let's check the fundamental score of Laboratorios Farmaceuticos ROVI based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1520.293
Price to Book Ratio (EOD)Between0-17.693
Net Profit Margin (MRQ)Greater than00.220
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.844
Current Ratio (MRQ)Greater than12.549
Debt to Asset Ratio (MRQ)Less than10.321
Debt to Equity Ratio (MRQ)Less than10.475
Return on Equity (MRQ)Greater than0.150.095
Return on Assets (MRQ)Greater than0.050.064
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Laboratorios Farmaceuticos ROVI based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.136
Ma 20Greater thanMa 5077.885
Ma 50Greater thanMa 10071.170
Ma 100Greater thanMa 20063.771
OpenGreater thanClose80.500
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Other Stockholders Equity  60,0751,27161,346-31261,034-18,11042,924-62,312-19,388



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets799,884
Total Liabilities256,390
Total Stockholder Equity539,387
 As reported
Total Liabilities 256,390
Total Stockholder Equity+ 539,387
Total Assets = 799,884

Assets

Total Assets799,884
Total Current Assets509,331
Long-term Assets290,553
Total Current Assets
Cash And Cash Equivalents 25,322
Net Receivables 143,314
Inventory 337,968
Total Current Assets  (as reported)509,331
Total Current Assets  (calculated)506,604
+/- 2,727
Long-term Assets
Property Plant Equipment 253,652
Intangible Assets 33,902
Long-term Assets Other 656
Long-term Assets  (as reported)290,553
Long-term Assets  (calculated)288,210
+/- 2,343

Liabilities & Shareholders' Equity

Total Current Liabilities199,843
Long-term Liabilities56,547
Total Stockholder Equity539,387
Total Current Liabilities
Short-term Debt 13,185
Short Long Term Debt 8,060
Accounts payable 107,593
Other Current Liabilities 79,065
Total Current Liabilities  (as reported)199,843
Total Current Liabilities  (calculated)207,903
+/- 8,060
Long-term Liabilities
Long term Debt 38,575
Capital Lease Obligations 18,792
Long-term Liabilities  (as reported)56,547
Long-term Liabilities  (calculated)57,367
+/- 820
Total Stockholder Equity
Common Stock3,241
Retained Earnings 555,534
Other Stockholders Equity -19,388
Total Stockholder Equity (as reported)539,387
Total Stockholder Equity (calculated)539,387
+/-0
Other
Capital Stock3,241
Cash and Short Term Investments 25,322
Common Stock Shares Outstanding 51,842
Liabilities and Stockholders Equity 799,884
Net Debt 40,105
Net Invested Capital 586,022
Net Working Capital 309,488
Property Plant and Equipment Gross 480,685
Short Long Term Debt Total 65,427



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-03-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
48,602
80,977
89,606
103,480
0
115,736
112,159
115,884
115,884
135,905
135,905
145,403
145,403
164,787
164,787
0
208,259
0
212,887
216,512
217,912
218,307
228,068
219,266
219,267
216,920
222,363
224,992
229,376
236,089
235,923
236,591
247,640
245,329
261,320
261,880
264,596
262,089
263,847
265,401
278,595
271,324
287,848
301,942
303,004
289,626
298,382
307,319
312,247
316,158
402,700
427,665
449,121
452,174
511,211
526,660
543,830
561,714
574,439
591,382
644,245
685,066
732,676
744,859
791,565
772,466
878,703
885,195
899,832
830,725
799,884
799,884830,725899,832885,195878,703772,466791,565744,859732,676685,066644,245591,382574,439561,714543,830526,660511,211452,174449,121427,665402,700316,158312,247307,319298,382289,626303,004301,942287,848271,324278,595265,401263,847262,089264,596261,880261,320245,329247,640236,591235,923236,089229,376224,992222,363216,920219,267219,266228,068218,307217,912216,512212,8870208,2590164,787164,787145,403145,403135,905135,905115,884115,884112,159115,7360103,48089,60680,97748,602
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
161,931
165,517
164,937
164,723
169,177
160,986
145,350
132,111
131,042
134,195
142,570
144,450
137,483
138,296
155,846
149,623
162,033
163,444
160,748
157,348
154,083
153,884
166,861
158,888
167,072
181,116
182,894
168,446
168,167
177,017
181,573
183,881
254,004
245,528
266,864
269,537
317,885
334,895
351,465
366,856
364,578
386,142
439,297
476,502
506,362
521,958
566,934
543,620
623,073
631,586
637,965
567,063
509,331
509,331567,063637,965631,586623,073543,620566,934521,958506,362476,502439,297386,142364,578366,856351,465334,895317,885269,537266,864245,528254,004183,881181,573177,017168,167168,446182,894181,116167,072158,888166,861153,884154,083157,348160,748163,444162,033149,623155,846138,296137,483144,450142,570134,195131,042132,111145,350160,986169,177164,723164,937165,517161,931000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
58,635
38,673
52,593
58,934
49,491
37,519
36,489
21,623
16,585
22,193
22,361
17,065
19,401
12,866
25,219
28,241
26,671
27,855
25,673
25,576
29,251
39,930
44,612
40,721
41,378
47,662
54,122
44,171
40,700
38,965
29,966
17,474
95,511
71,308
66,680
42,525
67,426
55,938
35,428
35,283
53,162
72,617
126,746
143,961
99,035
101,736
157,627
97,639
124,945
141,462
153,812
56,377
25,322
25,32256,377153,812141,462124,94597,639157,627101,73699,035143,961126,74672,61753,16235,28335,42855,93867,42642,52566,68071,30895,51117,47429,96638,96540,70044,17154,12247,66241,37840,72144,61239,93029,25125,57625,67327,85526,67128,24125,21912,86619,40117,06522,36122,19316,58521,62336,48937,51949,49158,93452,59338,67358,635000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,000
6,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32
0
32
0
47
0
59
0
67
0
69
0
80
0
0
0
0
0
0
0
0
0
1,225
0
-65
-65
1,606
-65
0
0-651,606-65-6501,225000000000800690670590470320320000000000000000006,0006,0000000000000000000000000
       Net Receivables 
20,736
27,976
28,478
27,414
0
40,531
39,398
44,742
44,742
46,506
46,506
42,537
42,537
58,919
58,919
0
56,079
0
60,317
60,113
62,366
65,573
71,203
72,912
58,017
58,633
57,037
60,518
62,400
66,999
57,988
64,024
63,337
57,905
66,572
66,361
63,754
58,693
59,584
52,236
59,014
52,557
56,664
61,422
54,036
50,453
50,330
56,268
58,799
62,343
62,200
62,456
70,218
72,738
89,895
87,362
78,386
93,895
82,046
94,336
110,624
109,596
150,172
169,159
121,426
150,182
180,011
161,318
126,379
139,133
143,314
143,314139,133126,379161,318180,011150,182121,426169,159150,172109,596110,62494,33682,04693,89578,38687,36289,89572,73870,21862,45662,20062,34358,79956,26850,33050,45354,03661,42256,66452,55759,01452,23659,58458,69363,75466,36166,57257,90563,33764,02457,98866,99962,40060,51857,03758,63358,01772,91271,20365,57362,36660,11360,317056,079058,91958,91942,53742,53746,50646,50644,74244,74239,39840,531027,41428,47827,97620,736
       Other Current Assets 
194
60
888
2,230
0
308
0
0
0
0
0
0
0
0
0
0
0
0
61,472
85,113
74,443
65,573
72,380
72,912
59,662
58,633
58,232
60,518
63,622
66,999
59,335
64,024
64,560
57,905
67,795
66,361
65,144
58,693
60,973
52,236
60,403
52,557
58,308
61,422
55,395
50,453
51,975
56,268
60,185
63,852
63,632
65,911
78,601
79,662
91,648
87,608
80,203
93,928
84,217
95,031
114,288
813
161,854
173,068
142,938
3,867
6,173
1,748
4,768
5,874
0
05,8744,7681,7486,1733,867142,938173,068161,854813114,28895,03184,21793,92880,20387,60891,64879,66278,60165,91163,63263,85260,18556,26851,97550,45355,39561,42258,30852,55760,40352,23660,97358,69365,14466,36167,79557,90564,56064,02459,33566,99963,62260,51858,23258,63359,66272,91272,38065,57374,44385,11361,47200000000000030802,23088860194
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50,956
50,995
52,975
53,584
58,891
58,280
73,917
84,809
91,321
90,797
86,806
91,639
98,440
98,295
91,794
95,706
99,287
98,436
103,848
104,741
109,764
111,517
111,734
112,436
120,776
120,826
120,110
121,180
130,215
130,302
130,674
132,277
148,696
182,137
182,257
182,637
193,326
191,765
192,365
194,858
209,861
205,240
204,948
208,564
226,314
222,901
224,631
228,846
255,630
253,609
261,867
263,662
290,553
290,553263,662261,867253,609255,630228,846224,631222,901226,314208,564204,948205,240209,861194,858192,365191,765193,326182,637182,257182,137148,696132,277130,674130,302130,215121,180120,110120,826120,776112,436111,734111,517109,764104,741103,84898,43699,28795,70691,79498,29598,44091,63986,80690,79791,32184,80973,91758,28058,89153,58452,97550,99550,956000000000000000000
       Property Plant Equipment 
3,208
5,549
11,332
14,034
0
17,863
21,577
26,401
26,401
29,817
29,817
31,290
31,290
32,539
32,539
0
40,975
0
42,659
42,644
42,842
43,077
45,857
46,580
47,411
49,394
53,791
53,724
54,725
56,098
60,199
59,840
62,235
65,138
73,593
72,496
77,227
77,864
81,803
80,725
80,400
80,813
82,822
81,370
81,089
81,724
89,056
89,129
89,095
90,592
95,837
117,283
121,064
122,988
131,608
130,755
131,293
136,862
155,395
154,962
159,426
165,191
181,775
179,126
182,648
187,474
215,541
215,463
223,785
226,655
253,652
253,652226,655223,785215,463215,541187,474182,648179,126181,775165,191159,426154,962155,395136,862131,293130,755131,608122,988121,064117,28395,83790,59289,09589,12989,05681,72481,08981,37082,82280,81380,40080,72581,80377,86477,22772,49673,59365,13862,23559,84060,19956,09854,72553,72453,79149,39447,41146,58045,85743,07742,84242,64442,659040,975032,53932,53931,29031,29029,81729,81726,40126,40121,57717,863014,03411,3325,5493,208
       Goodwill 
0
1,441
1,441
1,441
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000000000000000001,4411,4411,4410
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,641
2,544
2,351
2,348
2,123
2,108
2,098
2,080
2,108
2,147
2,098
1,972
1,914
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,9141,9722,0982,1472,1082,0802,0982,1082,1232,3482,3512,5442,641000000000000000000000000000000000000000000
       Intangible Assets 
1,191
1,449
1,460
1,469
0
731
749
762
762
745
745
743
743
974
974
0
1,275
0
2,290
2,320
2,686
2,668
2,736
2,754
2,892
2,937
3,176
3,155
5,779
8,702
14,468
14,393
14,742
15,239
17,206
17,287
17,567
17,812
18,881
18,551
18,665
18,603
24,872
26,459
25,829
25,212
27,078
26,589
26,233
25,993
34,650
47,395
47,012
46,130
45,079
0
43,151
0
41,413
40,522
39,690
38,887
38,558
0
36,901
0
35,744
0
34,249
0
33,902
33,902034,249035,744036,901038,55838,88739,69040,52241,413043,151045,07946,13047,01247,39534,65025,99326,23326,58927,07825,21225,82926,45924,87218,60318,66518,55118,88117,81217,56717,28717,20615,23914,74214,39314,4688,7025,7793,1553,1762,9372,8922,7542,7362,6682,6862,3202,29001,275097497474374374574576276274973101,4691,4601,4491,191
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,156
2,171
3,600
3,593
6,325
6,132
17,786
26,531
28,281
27,374
19,336
19,287
16,256
16,256
6,683
6,811
208
208
209
209
209
2,759
2,860
2,917
2,830
2,659
2,466
2,463
2,188
2,173
2,163
2,145
2,173
2,212
2,163
2,037
1,979
2,011
1,956
1,945
1,948
1,996
2,079
2,143
2,131
2,211
1,290
2,184
2,267
2,278
1,671
2,781
656
6562,7811,6712,2782,2672,1841,2902,2112,1312,1432,0791,9961,9481,9451,9562,0111,9792,0372,1632,2122,1732,1452,1632,1732,1882,4632,4662,6592,8302,9172,8602,7592092092092082086,8116,68316,25616,25619,28719,33627,37428,28126,53117,7866,1326,3253,5933,6002,1712,156000000000000000000
> Total Liabilities 
30,797
40,038
44,308
62,126
0
65,360
60,235
52,722
52,722
67,190
67,190
75,156
75,156
77,582
77,582
0
109,681
0
108,753
107,569
109,640
106,855
114,087
100,158
99,021
93,346
95,916
92,513
95,983
95,867
91,459
86,623
96,483
90,837
102,850
96,742
105,326
99,864
99,062
91,419
103,095
92,311
104,442
111,921
112,882
98,190
106,695
108,694
119,133
115,057
115,228
133,213
149,814
138,367
188,825
190,347
191,587
192,257
200,739
194,038
240,383
232,034
261,700
319,160
391,215
329,182
357,324
316,399
380,047
276,087
256,390
256,390276,087380,047316,399357,324329,182391,215319,160261,700232,034240,383194,038200,739192,257191,587190,347188,825138,367149,814133,213115,228115,057119,133108,694106,69598,190112,882111,921104,44292,311103,09591,41999,06299,864105,32696,742102,85090,83796,48386,62391,45995,86795,98392,51395,91693,34699,021100,158114,087106,855109,640107,569108,7530109,681077,58277,58275,15675,15667,19067,19052,72252,72260,23565,360062,12644,30840,03830,797
   > Total Current Liabilities 
24,127
26,068
31,904
40,249
0
40,123
34,520
27,221
27,221
35,413
35,413
41,755
41,755
38,719
38,719
0
55,035
0
51,627
48,303
51,956
49,246
56,756
52,281
56,862
52,144
55,132
52,507
61,467
62,215
58,340
54,082
63,821
46,822
62,117
57,164
68,146
56,092
59,226
53,856
68,526
60,447
76,442
66,686
69,857
58,717
73,223
80,186
91,191
85,839
87,512
89,398
104,913
95,036
106,709
108,534
111,556
111,815
122,889
118,342
167,373
159,434
190,388
248,705
320,569
258,337
293,887
255,405
321,594
220,774
199,843
199,843220,774321,594255,405293,887258,337320,569248,705190,388159,434167,373118,342122,889111,815111,556108,534106,70995,036104,91389,39887,51285,83991,19180,18673,22358,71769,85766,68676,44260,44768,52653,85659,22656,09268,14657,16462,11746,82263,82154,08258,34062,21561,46752,50755,13252,14456,86252,28156,75649,24651,95648,30351,627055,035038,71938,71941,75541,75535,41335,41327,22127,22134,52040,123040,24931,90426,06824,127
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,545
1,959
8,120
1,983
8,780
9,255
9,339
8,406
8,625
8,400
8,718
4,286
4,409
4,274
4,949
5,843
8,241
10,147
11,479
12,671
13,353
12,966
13,001
13,024
14,303
16,208
18,135
19,069
18,878
17,635
17,453
14,614
10,883
12,572
5,441
5,768
0
5,097
5,335
5,584
5,214
6,400
6,225
6,751
6,814
12,697
12,427
11,960
11,580
13,185
13,18511,58011,96012,42712,6976,8146,7516,2256,4005,2145,5845,3355,09705,7685,44112,57210,88314,61417,45317,63518,87819,06918,13516,20814,30313,02413,00112,96613,35312,67111,47910,1478,2415,8434,9494,2744,4094,2868,7188,4008,6258,4069,3399,2558,7801,9838,1201,9598,545000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,794
51,300
49,135
14,303
16,208
18,135
19,069
18,878
17,635
17,453
14,614
7,283
9,112
0
0
0
2,028
0
0
0
2,959
0
2,788
0
8,238
0
0
0
8,060
8,0600008,23802,78802,9590002,0280009,1127,28314,61417,45317,63518,87819,06918,13516,20814,30349,13551,30033,794000000000000000000000000000000000000000000
       Accounts payable 
16,730
12,136
18,119
22,469
0
24,246
23,042
18,598
18,598
23,643
23,643
32,399
32,399
24,877
24,877
0
23,329
0
46,053
42,204
8,578
34,589
51,209
38,313
27,235
37,352
32,005
37,141
46,691
46,887
34,421
39,250
34,714
39,665
46,601
49,275
35,113
44,640
36,982
39,080
37,057
44,011
50,221
49,926
35,698
40,017
42,129
57,881
50,970
63,413
47,875
70,125
89,402
80,166
68,770
100,487
85,805
86,544
63,452
81,178
71,516
101,430
97,407
133,376
97,564
126,237
128,484
135,331
107,934
113,637
107,593
107,593113,637107,934135,331128,484126,23797,564133,37697,407101,43071,51681,17863,45286,54485,805100,48768,77080,16689,40270,12547,87563,41350,97057,88142,12940,01735,69849,92650,22144,01137,05739,08036,98244,64035,11349,27546,60139,66534,71439,25034,42146,88746,69137,14132,00537,35227,23538,31351,20934,5898,57842,20446,053023,329024,87724,87732,39932,39923,64323,64318,59818,59823,04224,246022,46918,11912,13616,730
       Other Current Liabilities 
6,626
11,523
11,607
11,055
0
12,811
8,681
4,606
4,606
6,250
6,250
2,546
2,546
8,033
8,033
0
21,091
0
5,574
6,099
43,207
5,917
3,588
5,605
27,644
43,364
13,872
6,027
6,370
6,703
15,519
6,114
24,821
2,748
11,242
2,940
27,190
3,211
12,097
3,297
18,798
3,083
13,255
3,759
21,135
4,397
14,886
4,170
21,152
3,548
22,002
1,820
897
3,987
25,367
2,606
19,983
25,268
54,340
30,732
89,359
52,790
85,900
109,104
216,254
125,286
37,805
9,021
109,380
19,263
79,065
79,06519,263109,3809,02137,805125,286216,254109,10485,90052,79089,35930,73254,34025,26819,9832,60625,3673,9878971,82022,0023,54821,1524,17014,8864,39721,1353,75913,2553,08318,7983,29712,0973,21127,1902,94011,2422,74824,8216,11415,5196,7036,3706,02713,87243,36427,6445,6053,5885,91743,2076,0995,574021,09108,0338,0332,5462,5466,2506,2504,6064,6068,68112,811011,05511,60711,5236,626
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
57,126
59,266
57,684
57,609
57,331
47,877
42,159
41,202
40,784
40,006
34,516
33,652
33,119
32,541
32,662
44,015
40,733
39,578
37,180
43,772
39,836
37,563
34,569
31,864
28,000
45,235
43,025
39,473
33,472
28,508
27,942
29,218
27,716
43,815
44,901
43,331
82,116
81,813
80,031
80,442
77,850
75,696
73,010
72,600
71,312
70,455
70,646
70,845
63,437
60,994
58,453
55,313
56,547
56,54755,31358,45360,99463,43770,84570,64670,45571,31272,60073,01075,69677,85080,44280,03181,81382,11643,33144,90143,81527,71629,21827,94228,50833,47239,47343,02545,23528,00031,86434,56937,56339,83643,77237,18039,57840,73344,01532,66232,54133,11933,65234,51640,00640,78441,20242,15947,87757,33157,60957,68459,26657,126000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66,378
0
59,441
0
54,540
0
0
0054,540059,441066,3780000000000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-8,545
-1,959
-8,120
-1,983
-8,780
-9,255
-9,339
-8,406
-8,625
-8,400
-8,718
-4,286
-4,409
-4,274
-4,949
-5,843
-8,241
-10,147
-11,479
-12,671
-13,353
-12,966
-13,001
-13,024
-14,303
-16,208
-18,135
-19,069
-18,878
-17,635
-17,453
4,495
-10,883
8,299
-5,441
-5,768
0
12,449
-5,335
-5,584
-5,214
11,263
-6,225
10,817
-6,814
5,159
-12,427
-11,960
-11,580
5,607
5,607-11,580-11,960-12,4275,159-6,81410,817-6,22511,263-5,214-5,584-5,33512,4490-5,768-5,4418,299-10,8834,495-17,453-17,635-18,878-19,069-18,135-16,208-14,303-13,024-13,001-12,966-13,353-12,671-11,479-10,147-8,241-5,843-4,949-4,274-4,409-4,286-8,718-8,400-8,625-8,406-9,339-9,255-8,780-1,983-8,120-1,959-8,545000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,240
0
6,113
0
8,429
0
8,386
0
8,371
0
8,150
0
7,929
0
7,708
0
7,487
0
7,266
0
7,045
0
6,824
0
6,603
0
0
0
0
00006,60306,82407,04507,26607,48707,70807,92908,15008,37108,38608,42906,11304,240000000000000000000000000000000000000000000
> Total Stockholder Equity
17,805
40,914
45,283
41,351
25,810
50,375
51,924
63,162
63,162
68,715
68,715
70,247
70,247
87,205
87,205
87,205
98,578
0
104,134
108,943
108,272
111,452
113,981
119,108
120,246
123,574
126,447
132,479
133,393
140,222
144,464
149,968
151,157
154,492
158,470
165,138
159,270
162,225
164,785
173,982
175,500
179,013
183,406
190,021
190,122
191,436
191,687
198,625
193,114
201,101
287,472
294,452
299,307
313,807
322,386
336,313
352,243
369,457
373,700
397,344
403,862
453,032
470,976
425,553
399,022
441,921
520,012
567,259
516,643
551,501
539,387
539,387551,501516,643567,259520,012441,921399,022425,553470,976453,032403,862397,344373,700369,457352,243336,313322,386313,807299,307294,452287,472201,101193,114198,625191,687191,436190,122190,021183,406179,013175,500173,982164,785162,225159,270165,138158,470154,492151,157149,968144,464140,222133,393132,479126,447123,574120,246119,108113,981111,452108,272108,943104,134098,57887,20587,20587,20570,24770,24768,71568,71563,16263,16251,92450,37525,81041,35145,28340,91417,805
   Common Stock
214
10,674
9,936
3,454
0
147
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
0
3,000
0
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,000
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,364
3,241
3,241
3,241
3,241
3,241
3,241
3,2413,2413,2413,2413,2413,2413,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,3643,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,0003,00003,00003,0003,0003,0003,0003,0003,0003,0003,0003,00014703,4549,93610,674214
   Retained Earnings 
2,035
30,233
34,351
37,704
0
50,174
48,861
60,048
60,048
68,478
68,478
71,045
71,045
85,482
85,482
0
97,405
0
102,496
107,348
12,874
109,674
112,047
5,257
12,959
16,632
125,206
130,664
132,325
137,506
141,965
147,895
148,923
153,846
157,685
164,211
162,893
165,982
169,299
178,721
180,389
184,005
188,510
194,934
194,845
196,243
196,496
203,411
198,117
206,202
204,687
211,823
216,820
231,742
241,057
256,392
273,448
293,516
302,215
329,550
338,711
390,754
445,426
498,453
472,475
384,351
456,031
502,010
451,719
504,667
555,534
555,534504,667451,719502,010456,031384,351472,475498,453445,426390,754338,711329,550302,215293,516273,448256,392241,057231,742216,820211,823204,687206,202198,117203,411196,496196,243194,845194,934188,510184,005180,389178,721169,299165,982162,893164,211157,685153,846148,923147,895141,965137,506132,325130,664125,20616,63212,9595,257112,047109,67412,874107,348102,496097,405085,48285,48271,04571,04568,47868,47860,04860,04848,86150,174037,70434,35130,2332,035
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
87,636
0
87,636
0
0
87,636
0
87,636
0
87,636
0
0
0087,636087,636087,6360087,636087,63600000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000-28,7200-23,876000000000-8,698-8,600-8,383-8,407-8,405-8,321-8,511-8,701-8,589-8,486-8,336-8,112-7,355-7,221-2,672-2,813-2,739-1,061-1,208-782-585-2,267-1,540-2,060-2,148-2,077-1,880-1,922-1,938-2,064-2,003-1,9600-1,8250-1,198-1,198-4,087-4,087-2,602-2,602000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,362
-1,405
92,398
-1,222
-1,066
110,851
104,287
103,942
-1,759
-1,185
-1,932
-284
-501
-927
-766
-2,354
-2,215
-2,073
-6,623
-6,757
-7,514
-7,739
-7,889
-7,992
-8,104
-7,913
-7,723
-7,807
-7,809
-7,786
-8,003
-8,101
79,421
79,265
79,123
78,701
77,965
76,557
75,431
72,577
68,121
64,430
61,787
-2
22,186
-76,264
-76,817
54,329
60,075
61,346
61,034
42,924
-19,388
-19,38842,92461,03461,34660,07554,329-76,817-76,26422,186-261,78764,43068,12172,57775,43176,55777,96578,70179,12379,26579,421-8,101-8,003-7,786-7,809-7,807-7,723-7,913-8,104-7,992-7,889-7,739-7,514-6,757-6,623-2,073-2,215-2,354-766-927-501-284-1,932-1,185-1,759103,942104,287110,851-1,066-1,22292,398-1,405-1,362000000000000000000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue829,509
Cost of Revenue-337,224
Gross Profit492,285492,285
 
Operating Income (+$)
Gross Profit492,285
Operating Expense-272,031
Operating Income220,254220,254
 
Operating Expense (+$)
Research Development0
Selling General Administrative16,223
Selling And Marketing Expenses21,754
Operating Expense272,03137,977
 
Net Interest Income (+$)
Interest Income7
Interest Expense-667
Other Finance Cost-1,216
Net Interest Income556
 
Pretax Income (+$)
Operating Income220,254
Net Interest Income556
Other Non-Operating Income Expenses0
Income Before Tax (EBT)220,408220,100
EBIT - interestExpense = 220,599
220,444
171,002
Interest Expense667
Earnings Before Interest and Taxes (EBIT)221,266221,075
Earnings Before Interest and Taxes (EBITDA)245,597
 
After tax Income (+$)
Income Before Tax220,408
Tax Provision-50,109
Net Income From Continuing Ops170,299170,299
Net Income170,335
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses609,255
Total Other Income/Expenses Net154-556
 

Technical Analysis of Rovi
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Rovi. The general trend of Rovi is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Rovi's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Laboratorios Farmaceuticos ROVI.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: .

The bearish price targets are: 79.90 > 64.25 > 61.10.

Tweet this
Laboratorios Farmaceuticos ROVI Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Laboratorios Farmaceuticos ROVI. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Laboratorios Farmaceuticos ROVI Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Laboratorios Farmaceuticos ROVI. The current macd is 2.65205574.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rovi price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Rovi. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Rovi price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Laboratorios Farmaceuticos ROVI Daily Moving Average Convergence/Divergence (MACD) ChartLaboratorios Farmaceuticos ROVI Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Laboratorios Farmaceuticos ROVI. The current adx is 28.54.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Rovi shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Laboratorios Farmaceuticos ROVI Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Laboratorios Farmaceuticos ROVI. The current sar is 75.16.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Laboratorios Farmaceuticos ROVI Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Laboratorios Farmaceuticos ROVI. The current rsi is 69.14. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Laboratorios Farmaceuticos ROVI Daily Relative Strength Index (RSI) ChartLaboratorios Farmaceuticos ROVI Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Laboratorios Farmaceuticos ROVI. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rovi price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Laboratorios Farmaceuticos ROVI Daily Stochastic Oscillator ChartLaboratorios Farmaceuticos ROVI Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Laboratorios Farmaceuticos ROVI. The current cci is 128.74.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Laboratorios Farmaceuticos ROVI Daily Commodity Channel Index (CCI) ChartLaboratorios Farmaceuticos ROVI Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Laboratorios Farmaceuticos ROVI. The current cmo is 39.93.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Laboratorios Farmaceuticos ROVI Daily Chande Momentum Oscillator (CMO) ChartLaboratorios Farmaceuticos ROVI Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Laboratorios Farmaceuticos ROVI. The current willr is -16.19047619.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Laboratorios Farmaceuticos ROVI Daily Williams %R ChartLaboratorios Farmaceuticos ROVI Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Laboratorios Farmaceuticos ROVI.

Laboratorios Farmaceuticos ROVI Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Laboratorios Farmaceuticos ROVI. The current atr is 1.91835735.

Laboratorios Farmaceuticos ROVI Daily Average True Range (ATR) ChartLaboratorios Farmaceuticos ROVI Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Laboratorios Farmaceuticos ROVI. The current obv is 3,777,590.

Laboratorios Farmaceuticos ROVI Daily On-Balance Volume (OBV) ChartLaboratorios Farmaceuticos ROVI Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Laboratorios Farmaceuticos ROVI. The current mfi is 51.19.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Laboratorios Farmaceuticos ROVI Daily Money Flow Index (MFI) ChartLaboratorios Farmaceuticos ROVI Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Laboratorios Farmaceuticos ROVI.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Laboratorios Farmaceuticos ROVI Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Laboratorios Farmaceuticos ROVI based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.136
Ma 20Greater thanMa 5077.885
Ma 50Greater thanMa 10071.170
Ma 100Greater thanMa 20063.771
OpenGreater thanClose80.500
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Rovi with someone you think should read this too:
  • Are you bullish or bearish on Rovi? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Rovi? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Laboratorios Farmaceuticos ROVI

I send you an email if I find something interesting about Laboratorios Farmaceuticos ROVI.


Comments

How you think about this?

Leave a comment

Stay informed about Laboratorios Farmaceuticos ROVI.

Receive notifications about Laboratorios Farmaceuticos ROVI in your mailbox!